Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction
Withdrawn before enrolling · Not applicable · Has a placebo group
Conditions studied: Acute Myocardial Infarction
In brief
The purpose of this study is to test the hypothesis that acetaminophen will reduce lipid peroxidation and isoprostane formation during reperfusion after percutaneous revascularization for acute myocardial infarction.
Key facts
- Study ID
- NCT01120769
- Run by
- Vanderbilt University
- People needed
- 0
- Starts
- 2011-07-01
- Expected to finish
- 2012-07-01
- Last updated by the study team
- 2015-12-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients presenting with STEMI
You may not qualify if…
- Duration of symptoms > 12 hours
- Suspected LM or proximal LAD occlusion (based on EKG interpretation)
- Hemodynamic instability
- Acetaminophen use in prior 24 hours
- Use of dipyridamole, or Aggrenox, a formulation of aspirin and extended-release dipyridamole, within 48 hours
- Current use of the following medications: phenytoin, valproic acid, phenobarbital, topiramate, rifampin, carbamazepine, cyclophosphamide, ritonavir, efavirenz, St. John's Wort
- Chronic heavy alcohol use
- Chronic liver disease (other than non-alcoholic fatty liver infiltration)
- Severe valvular heart disease
- Stroke in the past 60 days
- Active major bleeding
- Major surgery in the past 30 days
- Ongoing treatment for active malignancy
- Life expectancy less than 12 months as determined by the patient's attending physician
- Pregnancy
- asthma or severe COPD
- active wheezing on presentation
- allergy or prior adverse reaction to adenosine
Where it is running
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.